Quick Answer
Shuttle Pharmaceuticals Holdings, Inc. reported Net Income Loss of -$11.72 million for the year ending 2025.
- Shuttle Pharmaceuticals Holdings, Inc. showed a decrease of -28.2% in Net Income Loss from 2024 to 2025.
- This data is from Shuttle Pharmaceuticals Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$129.3 thousand | Q2 2021: -$346.8 thousand | Q3 2021: -$217.0 thousand | Q1 2022: -$681.8 thousand | Q2 2022: -$597.3 thousand | Q3 2022: -$998.4 thousand | Q1 2023: -$975.1 thousand | Q2 2023: -$2.18 million | Q3 2023: -$1.79 million | Q1 2024: -$1.73 million | Q2 2024: -$2.03 million | Q3 2024: -$3.78 million | Q1 2025: -$3.05 million | Q2 2025: -$3.71 million | Q3 2025: -$2.35 million.
- Over the full 5 years of available data (2021 to 2025), Shuttle Pharmaceuticals Holdings, Inc.'s Net Income Loss has declined by 917.4%.
- Historical annual values: Fiscal year 2025: -$11.72 million | Fiscal year 2024: -$9.14 million | Fiscal year 2023: -$6.59 million | Fiscal year 2022: -$3.03 million | Fiscal year 2021: -$1.15 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: